Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma

Osteosarcoma is a rare, aggressive bone cancer that most often affects children, adolescents, and young adults. Patients who develop metastatic disease face particularly poor outcomes, with a five-year survival rate of less than 30% ¹. The past 40 years have brought little improvement in survival outcomes for patients with osteosarcoma, underscoring a critical need for … Continued The post Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma appeared first on Healx .